What this pack is
DIAMICRON MR is the brand name in this record; gliclazide is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
DIAMICRON MRGeneric namegliclazide
Mainland China pack-name cue达美康®Historical or public source cue · verify the current target-market record · Open reference ↗
How this medicine works
TGA-released DIAMICRON MR product information describes gliclazide as an oral sulfonylurea that can lower blood glucose by stimulating insulin secretion from pancreatic beta cells. This explains an active-ingredient pathway only. The exact product identity in this dossier remains the DIAMICRON 60 mg MR modified-release tablet in ARTG 154042; mechanism does not determine anyone's glucose, suitability, tablet count, meals, co-use, pausing or substitution.
Read source: Australia ↗Historical public record · reviewed 2026-08-28More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- Mainland China pack-name cue
- 达美康®
- International brand name
- DIAMICRON MR
- Source-scoped market brand names
- 达美康 · Mainland China (2025 public hospital record)Source-scoped evidence ↗Qingdao Third People's Hospital's public record dated 26 May 2025 lists gliclazide modified-release tablets (达美康), 15 × 60 mg and Servier (Tianjin) Pharmaceutical Co., Ltd. This is a Chinese pack-name search clue, not evidence of current authorization, price or availability. The Australian DIAMICRON 60 mg MR leaflet below belongs to a separate market and does not establish instructions or interchangeability for a Chinese pack.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- gliclazide
- Dosage-form class
- Gliclazide 60 mg MR (modified release) oral tablet; blister pack as listed in TGA ARTG 154042
- Route
- Oral
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
Mainland China trade-name search cue:达美康®. This is a historical/public cue for reading pack text. It does not establish current approval, holder, supply or sale eligibility. Open reference ↗
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
1 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
AU · TGA ARTG 154042 (verified 26 Aug 2026)
60 mg labelled per tablet; MR modified-release tablet; blister pack (Australian TGA ARTG)
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- ARTG 154042
- Form and route
- DIAMICRON 60 mg MR gliclazide modified-release oral tablet · oral (product-identity field)
- Container
- blister pack
- gliclazide
- 60 mgLabelled amount per tablet; not an individual's tablet count, schedule or conversion instruction
PACKAGE-VISUAL STATUS
The TGA product-level record and official electronic leaflets were reviewed, but no one-to-one official package image was retained, so no package visual is shown
This dossier retains DIAMICRON 60 mg MR, gliclazide 60 mg tablets, the MR modified-release form, blister packaging and PI/CMI routes in TGA ARTG 154042. No official package image that can be matched one-to-one to this exact ARTG presentation was retained; to avoid treating a retail image, version-uncertain image, another-market image or immediate-release-tablet image as an exact DIAMICRON MR package, the page withholds package imagery and retains the official electronic leaflets for enlarged reading.
LABEL READING · NOT A PRESCRIPTION
DIAMICRON MR label reading: 60 mg and MR identify an exact tablet first
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
This module reads only DIAMICRON 60 mg MR, gliclazide, 60 mg per tablet, modified-release form and blister packaging in TGA ARTG 154042 and its official PI/CMI routes. It provides no individual tablet count, start, missed-use handling, meals, splitting, crushing, co-use, stopping, switching or purchase plan.
- Check DIAMICRON MR, gliclazide, 60 mg per tablet, MR (modified release), blister pack, ARTG 154042 and target market together. 60 mg is the labelled amount for this exact Australian modified-release tablet, not a web rule for personal tablet counts, adding strengths or replacing it with an immediate-release tablet.
- MR is part of dosage-form identity, not just letters after a name. A gliclazide immediate-release tablet, another sponsor's product, another modified-release product or another-market pack is not the same product merely because a generic name or milligram number matches; none becomes automatically interchangeable or suitable for self-directed co-use.
- The PI/CMI are official electronic-leaflet routes for the exact product. Questions about low blood glucose, prior reactions, kidney/liver problems, another glucose-lowering medicine, alcohol, OTC products or supplements require the actual pack, current prescription and complete medicine list to be checked item by item by a pharmacist or prescriber against current documents; this page does not decide continuation, pausing, make-up use or a treatment change.
- For altered consciousness, seizure, fainting, breathing difficulty, serious allergic features or another acute severe concern, use local urgent and medical pathways; do not wait for a web search or self-add, stop or counteract with another pack based on this page.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkTGA · Australia · Regulatory product record or public product information · 2026-08-28
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- Australia · 3
- See original document · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeAustralian TGA: DIAMICRON 60 mg MR gliclazide 60 mg tablet blister pack (ARTG 154042) ↗Current regulatory record · reviewed 2026-08-28
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- TGA · Australia · Regulatory product record or public product information · 2026-08-28Australian TGA eBS: DIAMICRON 60 mg MR Product Information (PI) official entry route ↗Current regulatory record · reviewed 2026-08-28
- Public product-record source · See original document · Public product record · 2026-09-12Australia: DIAMICRON 60 mg MR Consumer Medicine Information (prepared July 2022; published by MIMS September 2022; historical version, current version unconfirmed; hosted by ACSQHC) ↗reviewed 2026-09-12
- TGA · Australia · Regulatory product record or public product information · 2026-08-28Australian TGA: DIAMICRON MR Product Information (FOI 067-1314; Pharmacology section; historical public document) ↗Historical public record · reviewed 2026-08-28
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about DIAMICRON MR (gliclazide). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
DIAMICRON MR is the brand in this record and gliclazide is the active-ingredient name. Check both with the dosage form (Gliclazide 60 mg MR (modified release) oral tablet; blister pack as listed in TGA ARTG 154042) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- Australian TGA: DIAMICRON 60 mg MR gliclazide 60 mg tablet blister pack (ARTG 154042) ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA eBS: DIAMICRON 60 mg MR Product Information (PI) official entry route ↗Current regulatory record · reviewed 2026-08-28
- Australia: DIAMICRON 60 mg MR Consumer Medicine Information (prepared July 2022; published by MIMS September 2022; historical version, current version unconfirmed; hosted by ACSQHC) ↗reviewed 2026-09-12
- Australian TGA: DIAMICRON MR Product Information (FOI 067-1314; Pharmacology section; historical public document) ↗Historical public record · reviewed 2026-08-28
HOW IT WORKS · NOT A TREATMENT PLAN
How gliclazide works: it stimulates insulin secretion from pancreatic beta cells (a mechanism, not a glucose plan)
- “Stimulates insulin secretion” cannot explain the cause of one glucose change, sweating, dizziness, weakness or another symptom, and it cannot tell a webpage how any person should respond. With an actual symptom or reading concern, take the real pack, prescription and complete medicine list to a local pharmacist, prescriber or appropriate medical support.
- Being glucose-lowering products, or both affecting insulin, does not make DIAMICRON MR self-combinable, time-separable, alternatable or substitutable with another gliclazide product, insulin, another glucose-lowering medicine, OTC product, supplement or alcohol. Dosage form, strength, target-market label and the complete medicine list need review together.
- MR (modified release) is part of exact tablet identity. A mechanism explanation does not authorise splitting, crushing, converting an immediate-release tablet and a modified-release tablet, or deriving a personal tablet count from a milligram number. For questions about appearance, swallowing, missed use, other medicines or lifestyle, the next step is the current official leaflet and professional review.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- Australian TGA: DIAMICRON 60 mg MR gliclazide 60 mg tablet blister pack (ARTG 154042) ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA eBS: DIAMICRON 60 mg MR Product Information (PI) official entry route ↗Current regulatory record · reviewed 2026-08-28
- Australian TGA eBS: DIAMICRON 60 mg MR Consumer Medicine Information (CMI) official entry route ↗Current regulatory record · reviewed 2026-08-28
- Australia: DIAMICRON 60 mg MR Consumer Medicine Information (prepared July 2022; published by MIMS September 2022; historical version, current version unconfirmed; hosted by ACSQHC) ↗reviewed 2026-09-12
- Australian TGA: DIAMICRON MR Product Information (FOI 067-1314; Pharmacology section; historical public document) ↗Historical public record · reviewed 2026-08-28
SOURCE-TRACEABLE ARCHIVE
DIAMICRON MRgliclazide
This page links to public primary-source material for DIAMICRON MR. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
TGA ARTG registration date
TGA ARTG 154042 lists 11 Nov 2009 as the ARTG date for DIAMICRON 60 mg MR gliclazide 60 mg tablet blister pack. This date locates only this Australian regulatory product record; it does not establish approval, supply, sale eligibility, originator/generic relationship or individual suitability in another market.
Australian TGA: DIAMICRON 60 mg MR (ARTG 154042) ↗Product-level record and PI/CMI entry routes verified
This review confirmed that TGA ARTG 154042 links to this product's Product Information (PI) and Consumer Medicine Information (CMI) routes. The PI/CMI are supplied to TGA by the relevant sponsor for publication; this page presents them only as primary reading routes and does not turn them into individual tablet-count, stopping, switching or purchase conclusions.
Australian TGA eBS: DIAMICRON 60 mg MR PI/CMI official entry routes ↗
MARKET SCOPE
Market-record boundary
Australia
TGA ARTG product-level record and official PI/CMI routes linkedThis page records only DIAMICRON 60 mg MR, gliclazide 60 mg tablets, the MR modified-release form and blister packaging in ARTG 154042; it does not authenticate a product or establish actual marketing, stock, purchase, individual tablet count, co-use, stopping, switching or interchangeability.
Mainland China, the United States, the EU, Japan and other markets
Current market record not establishedNo local trade name, approval, packaging, supply, sale eligibility, originator/generic relationship or interchangeability is inferred from the Australian ARTG name, date, sponsor, PI/CMI or blister pack; every market requires separate checking against current local regulatory material.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
RECORD FAQ
Record questions
Can DIAMICRON MR's 60 mg, MR and blister pack tell me how many to take or whether I can change to an immediate-release gliclazide tablet?
No. These fields identify only the exact Australian modified-release tablet in TGA ARTG 154042. A shared generic name, nearby mg number, similar brand or package wording does not establish self-initiation, increase, make-up use, splitting, crushing, stopping, co-use, alternation or substitution; have a pharmacist or prescriber review the actual pack, current prescription and complete medicine list.
Why does the page link the PI/CMI without directly telling me to change use?
The PI/CMI are official primary reading routes for this exact product, but treatment decisions require the prescription, actual pack, other medicines, prior reactions and health status to be reviewed together. Do not self-stop, switch, increase, reduce or separate timing from a webpage, headline or one leaflet section alone.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.